Skip to main content
Top
Published in: AIDS and Behavior 1/2013

01-01-2013 | Original Paper

Barriers to Medication Adherence in Behaviorally and Perinatally Infected Youth Living with HIV

Authors: Karen MacDonell, Sylvie Naar-King, Heather Huszti, Marvin Belzer

Published in: AIDS and Behavior | Issue 1/2013

Login to get access

Abstract

The study explored barriers to antiretroviral medication adherence in perinatally and behaviorally HIV infected adolescents and young adults in a cross-sectional, multisite sample. The study included a subset of a convenience sample from a cross-sectional analysis. Participants were youth with HIV ages 12–24 who were prescribed HIV medication and reported missing medication in the past 7 days (n = 484, 28.4 % of protocol sample). The top barriers were similar for perinatally and behaviorally infected youth, but perinatally infected youth reported significantly more barriers. Forgetting, not feeling like taking medication and not wanting to be reminded of HIV infection were the most common barriers reported. Number of barriers was significantly correlated with percent of doses missed, viral load, and psychological distress for perinatally infected youth and with doses missed, psychological distress, and substance use for behaviorally infected youth. Interventions to improve adherence to HIV medications should not only address forgetfulness and choosing not to take medications, but also consider route of infection.
Literature
1.
go back to reference Joint United Nations Programme on HIV/AIDS. Report on the global AIDS epidemic. Mexico City, August: International AIDS Conference; 2008. Joint United Nations Programme on HIV/AIDS. Report on the global AIDS epidemic. Mexico City, August: International AIDS Conference; 2008.
2.
go back to reference Arnett JJ. Emerging adulthood: the winding road from the late teens through the twenties. New York: Oxford University Press; 2004. Arnett JJ. Emerging adulthood: the winding road from the late teens through the twenties. New York: Oxford University Press; 2004.
3.
go back to reference Simoni JM, Montgomery A, Martin E, New M, Demas PA, Rana S. Adherence to Antiretroviral Therapy for pediatric HIV infection: a qualitative systematic review with recommendations for research and clinical management. Pediatrics. 2007;119:e1371–83.PubMedCrossRef Simoni JM, Montgomery A, Martin E, New M, Demas PA, Rana S. Adherence to Antiretroviral Therapy for pediatric HIV infection: a qualitative systematic review with recommendations for research and clinical management. Pediatrics. 2007;119:e1371–83.PubMedCrossRef
4.
go back to reference Hazra R, Siberry GK, Mofenson LM. Growing up with HIV: children, adolescents, and young adults with perinatally acquired HIV infection. Annu Rev Med. 2010;61:169–85.PubMedCrossRef Hazra R, Siberry GK, Mofenson LM. Growing up with HIV: children, adolescents, and young adults with perinatally acquired HIV infection. Annu Rev Med. 2010;61:169–85.PubMedCrossRef
5.
go back to reference Koenig LJ, Nesheim S, Abramowitz S. Adolescents with perinatally acquired HIV: emerging behavioral and health needs for long-term survivors. Curr Opin Obstet Gynecol. 2011;23(5):321–7.PubMedCrossRef Koenig LJ, Nesheim S, Abramowitz S. Adolescents with perinatally acquired HIV: emerging behavioral and health needs for long-term survivors. Curr Opin Obstet Gynecol. 2011;23(5):321–7.PubMedCrossRef
6.
go back to reference Foster C, Fidler S. Adolescents with perinatally acquired HIV-1 Infection. Eur Infect Dis. 2011;5(1):10–6. Foster C, Fidler S. Adolescents with perinatally acquired HIV-1 Infection. Eur Infect Dis. 2011;5(1):10–6.
7.
go back to reference Rudy B, Murphy D, Harris R, Muenz L, Ellen J. Prevalence and interactions of patient-related risks for nonadherence to antiretroviral therapy among perinatally infected youth in the United States. AIDS Patient Care STDs. 2010;24(2):97–104.PubMedCrossRef Rudy B, Murphy D, Harris R, Muenz L, Ellen J. Prevalence and interactions of patient-related risks for nonadherence to antiretroviral therapy among perinatally infected youth in the United States. AIDS Patient Care STDs. 2010;24(2):97–104.PubMedCrossRef
8.
go back to reference Bangsberg DR, Perry S, Charlebois ED, et al. Non-adherence to highly active antiretroviral therapy predicts progression to AIDS. AIDS. 2001;15:1181–3.PubMedCrossRef Bangsberg DR, Perry S, Charlebois ED, et al. Non-adherence to highly active antiretroviral therapy predicts progression to AIDS. AIDS. 2001;15:1181–3.PubMedCrossRef
9.
go back to reference Murphy DA, Sarr M, Durako SJ, Moscicki AB, Wilson CM, Muenz LR. Barriers to HAART adherence among Human Immunodeficiency Virus-infected adolescents. Arch Pediatr Adolesc Med. 2003;157:249–55.PubMedCrossRef Murphy DA, Sarr M, Durako SJ, Moscicki AB, Wilson CM, Muenz LR. Barriers to HAART adherence among Human Immunodeficiency Virus-infected adolescents. Arch Pediatr Adolesc Med. 2003;157:249–55.PubMedCrossRef
10.
go back to reference MacDonell KE, Naar-King S, Murphy DA, Parsons JT, Huszti H. Situational temptation for HIV medication adherence in high-risk youth. AIDS Patient Care STDs. 2011;25(1):47–52.PubMedCrossRef MacDonell KE, Naar-King S, Murphy DA, Parsons JT, Huszti H. Situational temptation for HIV medication adherence in high-risk youth. AIDS Patient Care STDs. 2011;25(1):47–52.PubMedCrossRef
11.
go back to reference Derogatis LR, Spencer PM. The brief symptom inventory (BSI): administration, and procedures manual-I. Baltimore, MD: Clinical Psychometric Research. Derogatis LR, Spencer PM. The brief symptom inventory (BSI): administration, and procedures manual-I. Baltimore, MD: Clinical Psychometric Research.
12.
go back to reference Knight JR, Shrier LA, Bravender TJ, Farrell M, Vander Bilt J, Shafer HJ. A new brief screen for adolescent substance abuse. Arch Pediatr Adolesc Med. 1999;53:591–6. Knight JR, Shrier LA, Bravender TJ, Farrell M, Vander Bilt J, Shafer HJ. A new brief screen for adolescent substance abuse. Arch Pediatr Adolesc Med. 1999;53:591–6.
13.
go back to reference Shiffman S, Stone AA, Hufford MR. Ecological momentary assessment. Ann Rev Clin Psychol. 2008;4:1–32.CrossRef Shiffman S, Stone AA, Hufford MR. Ecological momentary assessment. Ann Rev Clin Psychol. 2008;4:1–32.CrossRef
14.
go back to reference Woods PW, Moran LM, Carey CL, Dawson MS. ludicello JE, Gibson S, Grant I, Atkinson JH, the HIV Neurobehavioral Research Center (HNRC) Group. Prospective memory in HIV infection: Is “remembering to remember” a unique predictor of self-reported medication management? Arch Clin Neuropsychol. 2008;23(3):257–70. Woods PW, Moran LM, Carey CL, Dawson MS. ludicello JE, Gibson S, Grant I, Atkinson JH, the HIV Neurobehavioral Research Center (HNRC) Group. Prospective memory in HIV infection: Is “remembering to remember” a unique predictor of self-reported medication management? Arch Clin Neuropsychol. 2008;23(3):257–70.
15.
go back to reference Gonzalez JS, Penedo FJ, Llabre MM, Duran RE, Antoni MH, Schneiderman N, Horne R. Physical symptoms, beliefs about medications, negative mood, and long-term HIV medication adherence. Ann Behav Med. 2007;34(1):46–55.PubMedCrossRef Gonzalez JS, Penedo FJ, Llabre MM, Duran RE, Antoni MH, Schneiderman N, Horne R. Physical symptoms, beliefs about medications, negative mood, and long-term HIV medication adherence. Ann Behav Med. 2007;34(1):46–55.PubMedCrossRef
16.
go back to reference Ammassari A, Murri R, Pezzotti P, et al. Self-reported symptoms and medication side effects influence adherence to highly active antiretroviral therapy in persons with HIV-infection. J Acquir Immune Defic Syndr. 2001;28:445–9.PubMed Ammassari A, Murri R, Pezzotti P, et al. Self-reported symptoms and medication side effects influence adherence to highly active antiretroviral therapy in persons with HIV-infection. J Acquir Immune Defic Syndr. 2001;28:445–9.PubMed
17.
go back to reference Roux P, Kouanfack C, Cohen J, Marcellin F, Boyer S, Delaporte E, Carrieri P, Laurent C, Spire B, the Stratall ANRS 12110/ESTHER Study Group. Adherence to antiretroviral treatment in HIV-positive patients in the Cameroon content: Promoting the use of medication reminder methods. J AIDS. 2011;57(6S):S40–S43. Roux P, Kouanfack C, Cohen J, Marcellin F, Boyer S, Delaporte E, Carrieri P, Laurent C, Spire B, the Stratall ANRS 12110/ESTHER Study Group. Adherence to antiretroviral treatment in HIV-positive patients in the Cameroon content: Promoting the use of medication reminder methods. J AIDS. 2011;57(6S):S40–S43.
18.
go back to reference Tanney MR, Naar-King S, MacDonell K. Depression and stigma in high-risk youth living with HIV: a multi-site study. J Pediatr Health Care (in press). Tanney MR, Naar-King S, MacDonell K. Depression and stigma in high-risk youth living with HIV: a multi-site study. J Pediatr Health Care (in press).
19.
go back to reference Rintamaki LS, Davis TC, Skripkauskas S, Bennett CL, Wolf MS. Social stigma concerns and HIV medication adherence. AIDS Patient Care STDs. 2006;20(5):359–68.PubMedCrossRef Rintamaki LS, Davis TC, Skripkauskas S, Bennett CL, Wolf MS. Social stigma concerns and HIV medication adherence. AIDS Patient Care STDs. 2006;20(5):359–68.PubMedCrossRef
20.
go back to reference Naar-King S, Kolmodin K, Parsons JT, Murphy DA. the ATN Protocol Team. Psychosocial factors and substance use in high risk youth living with HIV: a multisite study. AIDS Care. 2010;22(4):475–82.PubMed Naar-King S, Kolmodin K, Parsons JT, Murphy DA. the ATN Protocol Team. Psychosocial factors and substance use in high risk youth living with HIV: a multisite study. AIDS Care. 2010;22(4):475–82.PubMed
21.
go back to reference British HIV Association/Medical Society for the Study of Venereal Diseases (MSSVD). Guidelines on provision of adherence support to individuals receiving antiretroviral therapy. http://www.aidsmap.com/cms1032065. Accessed February 12, 2012; 2002. British HIV Association/Medical Society for the Study of Venereal Diseases (MSSVD). Guidelines on provision of adherence support to individuals receiving antiretroviral therapy. http://​www.​aidsmap.​com/​cms1032065. Accessed February 12, 2012; 2002.
22.
go back to reference Stone A, Shiffman S. Ecological momentary assessment (EMA) in behavioral medicine. Ann Behav Med. 1994;16(3):199–202. Stone A, Shiffman S. Ecological momentary assessment (EMA) in behavioral medicine. Ann Behav Med. 1994;16(3):199–202.
23.
go back to reference Haberer J, Kahane J, Kigozi I, Emenyonu N, Hunt P, Martin J, Bangsberg D. Real-time adherence monitoring for HIV antiretroviral therapy. AIDS Behav. 2010;14:1340–6.PubMedCrossRef Haberer J, Kahane J, Kigozi I, Emenyonu N, Hunt P, Martin J, Bangsberg D. Real-time adherence monitoring for HIV antiretroviral therapy. AIDS Behav. 2010;14:1340–6.PubMedCrossRef
25.
go back to reference Duncan LG, Moskowitz JT, Neilands TB, Dilworth SE, Hecht FM, Johnson MO. Mindfulness-based stress reduction for HIV treatment side effects: a randomized, wait-list controlled trial. J Pain Symptom Manage. 2012;43(2):161–71.PubMedCrossRef Duncan LG, Moskowitz JT, Neilands TB, Dilworth SE, Hecht FM, Johnson MO. Mindfulness-based stress reduction for HIV treatment side effects: a randomized, wait-list controlled trial. J Pain Symptom Manage. 2012;43(2):161–71.PubMedCrossRef
Metadata
Title
Barriers to Medication Adherence in Behaviorally and Perinatally Infected Youth Living with HIV
Authors
Karen MacDonell
Sylvie Naar-King
Heather Huszti
Marvin Belzer
Publication date
01-01-2013
Publisher
Springer US
Published in
AIDS and Behavior / Issue 1/2013
Print ISSN: 1090-7165
Electronic ISSN: 1573-3254
DOI
https://doi.org/10.1007/s10461-012-0364-1

Other articles of this Issue 1/2013

AIDS and Behavior 1/2013 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine